DDInter1838 DDInter1376
Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine).
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Tositumomab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capsicum
Tositumomab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duloxetine
Tositumomab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anakinra
Tositumomab {u} may lead to a major life threatening interaction when taken with {v} Measles virus vaccine live attenuated
Tositumomab {u} may lead to a major life threatening interaction when taken with {v} Bivalirudin
Tositumomab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Ketorolac
Tositumomab may cause a minor interaction that can limit clinical effects when taken with Capsicum
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra
Tositumomab may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Tositumomab may lead to a major life threatening interaction when taken with Bivalirudin
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Ketorolac and Tositumomab may lead to a major life threatening interaction when taken with Ketorolac